PE/Cyanine7 anti-human TIGIT (VSTM3) | BioLegend 372713 product information

product summary

company name :

BioLegend

other brands :

Babco, Signet, Sternberger Monoclonals, Senetek, Covance

product type :

antibody

product name :

PE/Cyanine7 anti-human TIGIT (VSTM3)

catalog :

372713

quantity :

25 tests

price :

183 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

A15153G

reactivity :

human, mouse

application :

flow cytometry

more info or order :

BioLegend product webpage

citations: 12

Published Application/Species/Sample/Dilution	Reference
flow cytometry; mouse	Jin Y, Lorvik K, Jin Y, Beck C, Sike A, Persiconi I, et al. Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer. Mol Ther Oncolytics. 2022;26:189-206 pubmed publisher
	Chen M, Wan Y, Li X, Xiang J, Chen X, Jiang J, et al. Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma. Cell Biosci. 2023;13:19 pubmed publisher
	Wang C, Choy F, Sanny A, Murakami T, Tan A, Lam K. An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses. Cells. 2023;12: pubmed publisher
	Lao L, Zeng W, Huang P, Chen H, Jia Z, Wang P, et al. CD8+ T cell-Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance. Cancer Immunol Res. 2023;11:320-338 pubmed publisher
	Herter J, Kiljan M, Kunze S, Reinscheid M, Ibruli O, Cai J, et al. Influence of chemoradiation on the immune microenvironment of cervical cancer patients. Strahlenther Onkol. 2023;199:121-130 pubmed publisher
	Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995-1007 pubmed publisher
	Li P, Yuan W, Wu R, Zeng C, Li K, Lu L. Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy. Front Oncol. 2022;12:917400 pubmed publisher
	Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, et al. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct Target Ther. 2022;7:85 pubmed publisher
	Cheng J, Myers T, Levinger C, Kumar P, Kumar J, Goshu B, et al. IL-27 induces IFN/STAT1-dependent genes and enhances function of TIGIT+ HIVGag-specific T cells. iScience. 2022;25:103588 pubmed publisher
	Qi J, Crinier A, Escali xe8 re B, Ye Y, Wang Z, Zhang T, et al. Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression. Cell Rep Med. 2021;2:100353 pubmed publisher
	Zhang X, Lu X, Cheung A, Zhang Q, Liu Z, Li Z, et al. Analysis of the Characteristics of TIGIT-Expressing CD3-CD56+NK Cells in Controlling Different Stages of HIV-1 Infection. Front Immunol. 2021;12:602492 pubmed publisher
	Mathewson N, Ashenberg O, Tirosh I, Gritsch S, Perez E, Marx S, et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell. 2021;184:1281-1298.e26 pubmed publisher

product information

Antigen :

TIGIT

Apps. Abbrev. :

Cat # :

372713

Clone :

A15153G

Item :

PE/Cyanine7 anti-human TIGIT (VSTM3)

Isotype :

Mouse IgG2a, κ

Other Names :

T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3, WUCAM

Size :

25 tests

Price (USD) :

183 USD

Reactivity :

Human

Clonality :

Monoclonal

Host :

Mouse

Conjugate/Tag/Label :

PE_CYANINE7

Immunogen :

Recombinant Human TIGIT.

Application Notes :

This clone can suppress anti-CD3 induced T cell proliferation in vitro based on in-house testing.This clone has been tested in-house and determined to not be suitable for applications in immunohistochemistry of paraffin-embedded tissue sections (IHC-P).Additional reported applications (for the relevant formats) include: Blocking^1.;

more info or order :

BioLegend product webpage